What Happens After the Last Dose

You’ve lost weight on a GLP-1 medication like semaglutide or tirzepatide—but what happens if you stop? Does the weight come back? Should you taper your GLP-1? Can you maintain your weight on a lower dose? Do you have to stay on a GLP-1 forever? In this video, I break down the latest research on GLP-1 discontinuation, weight regain, GLP-1 tapering, maintenance therapy, obesity treatment, and long-term weight maintenance—including important new research published in 2026. We’ll look at: STEP 1: What happened when people stopped semaglutide after 68 weeks? STEP 4: What happened when people switched from semaglutide to placebo? SURMOUNT-4: What tirzepatide withdrawal tells us about weight regain. New 2026 meta-analyses: How much weight do people regain after stopping weight-loss medications? SURMOUNT-MAINTAIN: Can a lower dose of tirzepatide maintain weight loss better than stopping completely? ATTAIN-MAINTAIN: Could switching from injectable semaglutide or tirzepatide to an oral GLP-1 medication help maintain weight loss? Muscle and exercise: Why resistance training, adequate protein, physical activity, and preservation of lean mass matter during weight loss and maintenance. The biology of weight regain: Why increased hunger after stopping a GLP-1 isn’t simply a matter of willpower. The goal isn’t simply: “How do I get off my GLP-1?” The better question may be: “What is the least intensive treatment strategy that allows me to maintain my health and weight loss?” ⸻ 🔎 Topics Covered GLP-1 weight regain • what happens when you stop Ozempic • what happens when you stop Wegovy • what happens when you stop Zepbound • what happens when you stop Mounjaro • stopping semaglutide • stopping tirzepatide • GLP-1 discontinuation • GLP-1 tapering • GLP-1 maintenance dose • GLP-1 weight maintenance • semaglutide weight regain • tirzepatide weight regain • obesity medication • weight loss maintenance • GLP-1 rebound weight gain • GLP-1 medications • Ozempic weight regain • Wegovy weight regain • Zepbound weight regain • Mounjaro weight regain • GLP-1 long-term treatment • GLP-1 research 2026 • obesity treatment 2026 • orforglipron • SURMOUNT-MAINTAIN • ATTAIN-MAINTAIN • STEP 1 • STEP 4 • SURMOUNT-4 ⸻ Medical Disclaimer This content is for educational and informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any medical condition or to replace individualized medical care. Do not start, stop, taper, increase, or decrease a prescription medication based solely on information in this video. If you are considering changing your GLP-1 medication, discuss your individual situation with your own healthcare professional. ⸻ Research Disclosure I am an endocrinologist and clinical researcher who participates in clinical research involving GLP-1 and other metabolic medications. My research involvement does not mean that I endorse or recommend any particular medication, company, or treatment. I am not being paid by a pharmaceutical company to make this video, and this video is not pharmaceutical advertising or sponsored content. The purpose of this video is to discuss and interpret the available scientific evidence. ⸻ References 1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. (PubMed) 2. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA. 2021. 3. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. 4. Budini B, et al. Trajectory of weight regain after cessation of weight-management medications: systematic review and nonlinear meta-regression. eClinicalMedicine. 2026. 5. West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026. 6. Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity: SURMOUNT-MAINTAIN. The Lancet. 2026. 7. Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: ATTAIN-MAINTAIN. Nature Medicine. 2026. 8. S-LiTE investigators. Exercise and liraglutide for weight-loss maintenance and cardiometabolic health. 2026. ⸻ Subscribe for evidence-based endocrinology, menopause & metabolic health I break down the latest research on GLP-1 medications, obesity, menopause, hormones, metabolic health, diabetes, and longevity—without the hype. Subscribe and turn on notifications so you don’t miss the next research update.